A detailed history of Bridgeway Capital Management, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 29,700 shares of BMY stock, worth $1.72 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
29,700
Previous 31,879 6.84%
Holding current value
$1.72 Million
Previous $1.32 Million 16.1%
% of portfolio
0.03%
Previous 0.03%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $86,419 - $112,763
-2,179 Reduced 6.84%
29,700 $1.54 Million
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $1.28 Million - $1.69 Million
31,879 New
31,879 $1.32 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $11,284 - $6.67 Million
-86,800 Reduced 36.6%
150,379 $10.7 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $2.35 Million - $2.58 Million
-32,300 Reduced 11.99%
237,179 $18.3 Million
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $1.53 Million - $1.83 Million
-24,850 Reduced 8.44%
269,479 $19.7 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $471,944 - $550,176
8,800 Added 3.08%
294,329 $18.4 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $1.88 Million - $2.2 Million
-31,700 Reduced 9.99%
285,529 $16.9 Million
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $143,940 - $156,751
-2,325 Reduced 0.73%
317,229 $21.2 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $5.76 Million - $6.48 Million
97,125 Added 43.67%
319,554 $20.2 Million
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $11.2 Million - $12.7 Million
-194,800 Reduced 46.69%
222,429 $13.8 Million
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $24 Million - $26.6 Million
417,229 New
417,229 $25.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.